June 2009

Contents

Editorial

• Volume 10 Number 5/6 May/June 2009

Conference reports

• 15th Annual Conference of the British HIV Association (BHIVA), 1-3 April 2009, Liverpool

• Superinfection identified in 2 out of 8 patients with unexpected viral load increases

• Peripheral DEXA scans to identify rates of reduced bone mineral density

• Vitamin D deficiency, supplementation and tenofovir

• High rate of lost and untested TB biopsy samples and low screening for latent TB

• 16th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2009, Montreal

• Assessing the cardiovascular impact of HIV, abacavir, and new signals for lopinavir/r

• Intensive smoking cessation programme reports limited success at 6 months

• HDL particle concentration predicts cardiovascular disease in SMART

• No effect of hormonal contraception on HIV disease progression in large multi-country cohort

• Pregnancy, family planning, and HIV acquisition in HPTN 039

• Progression and regression of pre-malignant cervical lesions in HIV-positive women from Soweto

• CD4 count >250 not predictive of rash-associated hepatoxicity among women initiating nevirapine-based ART in Zambia, Thailand, and Kenya

• HIV testing of infants at immunisation clinics in Kwazulu-Natal

• Rapid HIV disease progression in South African infants co-infected with cytomegalovirus (CMV)

• Pharmacokinetic studies in very young infants

• Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicin

• PI-based ART in children with HIV and HIV/TB coinfection in South Africa

• Etravirine dose selection in children aged 6 to 17

• Preliminary results from first paediatric raltegravir study

• 10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam

• Efavirenz lowers levels of darunavir given as 900/100mg once daily with ritonavir

• How much (or how little) ritonavir do you need to boost another PI?

• Genetic markers linked to early discontinuation of three antiretrovirals

• 4th South African AIDS Conference, 31 March-3 April 2009, Durban, South Africa

• HAART coverage and unmet need in South Africa

Antiretrovirals

• EMEA positive opinion on using tipranavir and darunavir in younger patients

• Lopinavir/r (Kaletra) cardiovascular risk requires FDA label changes

• NEJM paper: NA-ACCORD cohort study on when to start treatment

• NA ACCORD results support the importance of the START study: response to researchers

• EMEA statement on abacavir and the risk of heart attack

Treatment access

• Access to HIV treatment for UK prisoners

PK and drug interactions

• Potential interactions between antiviral treatment for swine flu (H1N1) and anti-HIV therapy

• Case reports of significant interactions between etravirine and raltegravir

Guidelines

• HIV and hepatitis coinfection guidelines (2009): online for comment

• US pregnancy guidelines updated (2009)

Cure-related research

• Update on (another) Berlin patient

Basic science and immunology

• Whole body CD4 T cell census questions role of gut

• Gut bacteria breach the barrier: further confirmation of microbial translocation in HIV infection

BHIVA news

• BHIVA research awards deadline

Other news

• Iowa: Gay man gets 25 years for one-time non-disclosure to a single complainant

• US denies entry to 60 HIV-positive Canadians

• Job vacancy: Editor post for of the Southern African Journal on HIV Medicine for the nursing profession

PDFs

• Volume 10 Number 5/6 May/June 2009 PDF